A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatrics patients with relapsed and refractory B-cell acute lymphoblastic leukemia
|Effective start/end date||3/2/15 → 11/1/22|
- NOVARTIS PHARMACEUTICALS CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.